# Glycemic Holter Study (Continuous Glucose Monitoring) -

> **NCT01193296** · PHASE4 · COMPLETED · sponsor: **Novartis** · enrollment: 36 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Vildagliptin
- **DRUG:** Sitagliptin

## Key facts

- **NCT ID:** NCT01193296
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2012-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01193296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01193296, "Glycemic Holter Study (Continuous Glucose Monitoring) -". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01193296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*